InsulinMar 15, 2026
NPH insulin has an image problem. It is older, cloudier, and requires more hands-on effort than the long-acting analogs that dominate modern prescribing. Yet the research paints a more nuanced picture: in type 2 diabetes, real-world data show similar or even better A1c results with NPH compared to pricier alternatives, and no reduction in serious hypoglycemia with those newer insulins. At 2 to 10 times less cost, NPH remains a genuinely effective basal insulin for a large number of people. The catch is that it demands more from the person using it.
Understanding where NPH truly falls short, and where the gap with analogs barely matters, can help you have a more honest conversation with your provider about what belongs in your regimen.
InsulinMar 15, 2026
Insulin's side effect profile is narrower than many people assume. Large, long-term trials point to just three main concerns: low blood sugar, modest weight gain, and local skin reactions at injection sites. Fears about insulin causing cancer or heart disease? Not supported by high-quality trial data.
But "narrow" doesn't mean "trivial." Hypoglycemia hits roughly 20% of basal insulin users each year and is a frequent driver of hospitalizations among older adults. Knowing which side effects actually warrant your attention, and which ones you can largely stop worrying about, changes how you approach insulin therapy day to day.
InsulinMar 15, 2026
You probably know your blood pressure and cholesterol levels. But chances are, you’ve never thought about your fasting insulin levels. As we age, our bodies change in subtle ways long before symptoms emerge. Muscles weaken. Blood vessels stiffen. Metabolism slows. One of the most telling and overlooked signals of these changes is how our bodies handle insulin.
Insulin is the hormone that tells your cells what to do with the food you eat. When it doesn’t work properly, the entire metabolic system begins to sputter. That’s why a simple fasting insulin test might offer an early glimpse into your body’s metabolic trajectory and your risk of chronic disease in the years ahead.
DiabetesMar 15, 2026
Lantus (insulin glargine U100) doesn't actually lower your HbA1c more than the older, cheaper insulin it was designed to replace. Compared to NPH insulin, Lantus achieves similar overall blood sugar control. Where it consistently wins is in reducing nocturnal and severe hypoglycemia, the kind of lows that wake you up at 3 a.m. shaking and sweating. That distinction matters more than many people realize, because fear of nighttime lows is one of the biggest barriers to getting insulin doses where they need to be.
The other thing worth knowing upfront: multiple biosimilar versions of Lantus now exist, and the clinical data show they are highly similar in how they work, how well they work, and how safe they are. The choice between Lantus and its copies increasingly comes down to cost, which device you prefer, and how your body responds individually.
Metabolic HealthMar 15, 2026
TMG (trimethylglycine, also called betaine) does something frustrating. According to meta-analysis data, it reliably lowers homocysteine by about 1.3 µmol/L, a marker linked to cardiovascular risk. But it simultaneously raises total and LDL cholesterol, particularly at doses of 4 grams per day or higher. That's not a minor footnote. It's the central tension in the TMG story, and it should shape how you think about supplementing.
Marketed for everything from heart health to gym performance to liver support, TMG is a naturally occurring compound involved in methylation, osmotic balance, and metabolism. The animal research looks impressive. The human research looks far more modest, and sometimes contradictory. Here's where things actually stand.
DiabetesMar 14, 2026
Most basal insulins ask you to be precise. Same time every day, no exceptions. Tresiba (insulin degludec) breaks that pattern. In clinical studies, people injected it anywhere from 8 to 40 hours apart without losing blood sugar control or compromising safety. That kind of flexibility is rare for a basal insulin, and it comes alongside another practical benefit: lower rates of nocturnal and overall hypoglycemia compared to older options like glargine and detemir.
If you're managing type 1 or type 2 diabetes and your current basal insulin feels like a rigid obligation, Tresiba offers something worth understanding.
InsulinMar 14, 2026
Over one-third of U.S. nursing home residents with diabetes are managed on sliding scale insulin alone, a method that multiple medical societies have flagged as potentially inappropriate for long-term use. The core problem: sliding scale insulin only reacts to high blood sugar after it happens. It never prevents it. Expert reviews describe the result as a "roller coaster" glucose pattern, and the research consistently shows it leads to worse control and more hypoglycemia than alternatives.
Yet it persists. Understanding why, and when it might still make sense, matters if you or someone you care about is being managed this way in a hospital or nursing home.
DiabetesMar 13, 2026
Fiasp delivers roughly double the insulin exposure in the first 30 minutes compared to standard insulin aspart, and about 70 to 75 percent more glucose-lowering in that same early window. Those are striking pharmacology numbers. Yet when you zoom out to the metrics most people care about, like A1c and time in range, the clinical advantage shrinks to something much more modest. That gap between impressive speed and underwhelming overall results is the central story of Fiasp, and understanding it helps you figure out whether it's worth the switch.
Fiasp is not a new insulin molecule. It is the same insulin aspart with two added ingredients: niacinamide (a form of vitamin B3) to speed absorption, and L-arginine to keep the formulation stable. That simple tweak shifts the entire action profile earlier, not bigger.
